Wave Neuroscience wins FDA clearance for precision PTSD therapy

Wave’s MeRT platform records individual patient brain data to tailor transcranial magnetic stimulation (TMS) therapy for PTSD treatment. Wave’s MeRT platform records individual patient brain data to tailor transcranial magnetic stimulation (TMS) therapy for PTSD treatment. According to data from the US Department of Veterans Affairs (VA), around 6% of the US population will have PTSD at some point in their lives. Credit: ArtemisDiana / Shutterstock.com The US Food and Drug Administration (FDA) has cleared Wave Neuroscience’s precision neuromodulation platform for post-traumatic stress disorder (PTSD) treatment, providing a personalised, biomarker-guided clinical treatment for US patients with the disorder. Wave’s magnetic…

Source: Medical Device Network